

R&D Tax Incentive Loan Facility Extension

Melbourne, Australia; 30 September 2026: **Cynata Therapeutics Limited** (ASX: “CYP”, “Cynata”, or the “Company”), advises that the maturity date of its Research and Development Tax Incentive (R&D TI) loan facility has been extended to 30 November 2026.

On 6 July 2026, the Company announced that it had entered into an R&D TI loan facility for a total of \$600,000 with a commercial lender. The loan must be repaid in full on the earlier of the receipt of the R&D TI rebate for the 2026 financial year, or the maturity date. The initial maturity date was 30 September 2026, but this has now been extended to 30 November 2026 by agreement with the lender.

The Company has submitted its R&D TI claim and tax return for the 2026 financial year. It is anticipated that the R&D TI rebate, which is expected to be approximately \$1.7m, will be received imminently, at which point the loan and accrued interest will be repaid in full, and the balance retained by the Company.

ENDS-

Authorised for release by the Board of Directors

CONTACT: investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automic Group](#).